Breaking News Instant updates and real-time market news.

BGNE

BeiGene

$126.50

0.63 (0.50%)

, GMDA

Gamida Cell

$9.50

(0.00%)

10:09
11/21/18
11/21
10:09
11/21/18
10:09

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BeiGene (BGNE) initiated with an Overweight at JPMorgan. 2. Gamida Cell (GMDA) initiated with an Outperform at BMO Capital and Oppenheimer. 3. Marker Therapeutics (MRKR) initiated with a Buy at Nomura Instinet. 4. Arco Platform (ARCE) initiated with a Buy at UBS. 5. nVent Electric (NVT) initiated with a Hold at Vertical Research. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

BGNE

BeiGene

$126.50

0.63 (0.50%)

GMDA

Gamida Cell

$9.50

(0.00%)

MRKR

Marker Therapeutics

$6.37

0.11 (1.76%)

ARCE

Arco Platform

$22.65

(0.00%)

NVT

nVent Electric

$24.43

0.25 (1.03%)

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 01

    Dec

  • 03

    Dec

  • 07

    Dec

BGNE BeiGene
$126.50

0.63 (0.50%)

11/20/18
JPMS
11/20/18
INITIATION
JPMS
Overweight
BeiGene initiated with an Overweight at JPMorgan
11/07/18
PIPR
11/07/18
NO CHANGE
Target $200
PIPR
Overweight
BeiGene produced 'strong quarter of commercial execution', says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren kept his Overweight rating and $200 price target on BeiGene (BGNE) after its Q3 results, saying the company had produced another "strong quarter of commercial execution as the Celgene (CELG) products were up significantly". The analyst notes that these products' contribution may be small to overall valuation, but sees their positive performance as a sign of BeiGene's ability to commercialize future, larger product opportunities in China. Van Buren adds that the NDA filing for zanubrutinib has a "negligible effect" on his valuation.
09/24/18
LEER
09/24/18
INITIATION
Target $215
LEER
Outperform
BeiGene initiated with an Outperform at Leerink
Leerink analyst Andrew Berens started BeiGene with an Outperform rating and $215 price target.
11/21/18
JPMS
11/21/18
INITIATION
Target $174
JPMS
Overweight
BeiGene initiated with an Overweight at JPMorgan
JPMorgan analyst Leon Chik last initiated coverage of BeiGene with an Overweight rating and $174 price target. The company over the past eight years has built a "strong innovative pipeline" composed of eight clinical candidates, three of which are already in Phase 3 clinical trials, Chik tells investors in a research note. He points out BeiGene also has exclusive licenses from Celgene for the China market to generate near-term sales and gross profits.
GMDA Gamida Cell
$9.50

(0.00%)

11/20/18
RBCM
11/20/18
INITIATION
Target $20
RBCM
Outperform
Gamida Cell initiated with an Outperform at RBC Capital
RBC Capital analyst Gregory Renza initiated Gamida Cell with an Outperform rating and a price target of $20. The analyst says the company's NiCord cell expansion technology using umbilical cord donor blood is a "promising late-stage asset with the potential to be a leading pharmaceutical-grade, universal curative stem cell graft for patients in need of hematopoietic stem cell transplants". Renza adds that NiCord has the potential to reach $1B in sales, stating that Gamida Cell is "an important cell therapy and transplant player" offering an attractive share opportunity.
11/21/18
BMOC
11/21/18
INITIATION
Target $19
BMOC
Outperform
Gamida Cell initiated with an Outperform at BMO Capital
BMO Capital analyst Matthew Luchini initiated Gamida Cell with an Outperform rating and a price target of $19. The analyst believes that the company's lead product NiCord may become a "universal treatment for patients with blood cancer needing stem cell transplant", offering "the benefits of umbilical cord blood transplantation". Luchini adds that the "promising" Phase I/II data should help de-risk the ongoing Phase III study and anticipates its peak sales to reach about $220M. If the platform is applied to cancer, the analyst believes that the Phase I data expected next year could unlock potential to upside opportunity of over $1B.
11/21/18
OPCO
11/21/18
INITIATION
Target $15
OPCO
Outperform
Gamida Cell initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach started Gamida Cell with an Outperform rating and $15 price target. The analyst sees Gamida's proprietary cell expansion technology as a "versatile approach for improving the performance of cell-based products." He believes the company's lead product, NiCord, could provide a safe and effective source of stem cells for transplant patients who lack compatible donors.
MRKR Marker Therapeutics
$6.37

0.11 (1.76%)

10/22/18
PIPR
10/22/18
INITIATION
Target $10
PIPR
Neutral
Marker Therapeutics initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff started Marker Therapeutics with a Neutral rating and $10 price target. The analyst believes the company's Multi Tumor-Associated Antigen Cell Therapy platform "offers several key advantages over current autologous CAR-T including improved manufacturing time and expense, and potentially safer, more durable response."
11/21/18
NOMU
11/21/18
INITIATION
Target $16
NOMU
Buy
Marker Therapeutics initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Christopher Marai started Marker Therapeutics with a Buy rating and $16 price target. The analyst believes the company's MultiTAA platform, which selects for and expands patient tumor-specific T cells by directly presenting a blend of tumor-associated antigens and cytokines in vitro, is "amenable to rapid approval." Further, Marker is trading at a discount to immunotherapy peers despite offering a "strong" de-risking data flow that will likely result in share upside over the next 12 months, Marai tells investors in a research note.
ARCE Arco Platform
$22.65

(0.00%)

10/22/18
MSCO
10/22/18
INITIATION
MSCO
Overweight
Arco Platform initiated with an Overweight at Morgan Stanley
10/22/18
10/22/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Domino's Pizza (DPZ) initiated with a Neutral at UBS. 2. Arco Platform (ARCE) initiated with an Overweight at Morgan Stanley, an Outperform at Itau BBA, and a Buy at Goldman Sachs. 3. Arvinas (ARVN) initiated with a Neutral at Goldman Sachs and an Overweight at Piper Jaffray. 4. Ra Medical Systems (RMED) initiated with a Buy at SunTrust as well as an Overweight at Cantor Fitzgerald and Piper Jaffray. 5. SurveyMonkey (SVMK) initiated with a Buy at SunTrust and BofA/Merrill, an Overweight at JPMorgan, and a Neutral at Credit Suisse and UBS. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/21/18
UBSW
11/21/18
INITIATION
Target $28
UBSW
Buy
Arco Platform initiated with a Buy at UBS
UBS analyst Maria Tereza Azevedo started Arco Platform with a Buy rating and $28 price target. The analyst views Arco as an "attractive investment proposition" given its "unique" product and market position in the private Brazilian K-12 learning system sector. She likes the company's software-as-a-service type and asset/regulatory-light business model.
10/22/18
MSCO
10/22/18
INITIATION
Target $27
MSCO
Overweight
Arco Platform initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Javier Martinez de Olcoz Cerdan initiated Arco Platform with an Overweight rating and $27 price target, stating that its "disruptive" one-stop, integrated education platform for private K-12 schools in Brazil has a strong track record of improving academic results and is accelerating incorporation of new clients. With just 5% of Brazil private students today, Martinez de Olcoz Cerdan believes the company has reached about 11% share on its addressable market and has room to cover about 25% long term, he tells investors.
NVT nVent Electric
$24.43

0.25 (1.03%)

05/18/18
SUSQ
05/18/18
INITIATION
Target $30
SUSQ
Positive
nVent Electric initiated with a Positive at Susquehanna
Susquehanna analyst Robert Barry initiated nVent Electric (NVT) with a Positive rating following its spinoff from Pentair (PNR). The analyst said his positive thesis reflects its projected earnings growth rate and opportunities for multiple expansion as the firm executes on its financial targets, which he thinks are achievable. Barry has a $30 price target on nVent Electric shares.
08/03/18
COWN
08/03/18
NO CHANGE
Target $52
COWN
Outperform
Pentair weakness would be a buying opportunity, says Cowen
Cowen analyst Joseph Giordano said any weakness in Pentair (PNR) would be a buying opportunity. He noted the spinoff of nVent Electric (NVT) allows it focus on its strengths and he now sees a realistic strategic vision for the company. Giordano reiterated his Outperform rating and $52 price target on Pentair shares.
10/26/18
GSCO
10/26/18
UPGRADE
Target $30
GSCO
Buy
nVent Electric upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analystJoseph Ritchie upgraded nVent Electric to Buy while lowering his price target for the shares to $30 from $31 following yesterday's Q3 results. The analyst views the valuation as attractive given the company's "improving growth."
11/20/18
VERT
11/20/18
INITIATION
Target $28
VERT
Hold
nVent Electric initiated with a Hold at Vertical Research
Price target $28.

TODAY'S FREE FLY STORIES

PFSW

PFSweb

$6.37

0.29 (4.77%)

16:14
03/18/19
03/18
16:14
03/18/19
16:14
Earnings
PFSweb sees FY19 SFE revenue increase in low-single digits »

PFSweb expects 2019 SFE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 27

    Mar

  • 28

    Mar

HQY

HealthEquity

$82.86

0.76 (0.93%)

16:14
03/18/19
03/18
16:14
03/18/19
16:14
Earnings
HealthEquity sees FY20 EPS 1.23-$1.29, consensus $1.31 »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 19

    Mar

  • 21

    Mar

  • 17

    Apr

PFSW

PFSweb

$6.29

0.21 (3.45%)

16:13
03/18/19
03/18
16:13
03/18/19
16:13
Earnings
PFSweb client bankruptcy to have negative impact on FY19 revenue »

One of PFSweb's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 27

    Mar

  • 28

    Mar

HQY

HealthEquity

$82.92

0.82 (1.00%)

16:12
03/18/19
03/18
16:12
03/18/19
16:12
Hot Stocks
HealthEquity reports Q4 EPS 27c, consensus 22c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 19

    Mar

  • 21

    Mar

  • 17

    Apr

RMAX

RE/MAX Holdings

$39.09

1.07 (2.81%)

, RDFN

Redfin

$18.50

0.04 (0.22%)

16:12
03/18/19
03/18
16:12
03/18/19
16:12
Hot Stocks
RE/MAX Holdings, Redfin announce exclusive referral relationship »

RE/MAX Holdings (RMAX)…

RMAX

RE/MAX Holdings

$39.09

1.07 (2.81%)

RDFN

Redfin

$18.50

0.04 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

FWRD

Forward Air

$64.27

0.66 (1.04%)

16:11
03/18/19
03/18
16:11
03/18/19
16:11
Hot Stocks
Forward Air to acquire FSA Logistix »

Forward Air Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFSW

PFSweb

$6.35

0.27 (4.44%)

16:11
03/18/19
03/18
16:11
03/18/19
16:11
Earnings
PFSweb reports Q4 EPS 17c, may not compare to consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 27

    Mar

  • 28

    Mar

ICAD

iCAD

$4.44

-0.02 (-0.45%)

16:10
03/18/19
03/18
16:10
03/18/19
16:10
Earnings
iCAD reports Q4 EPS (20c), two-estimate consensus (10c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

VERU

Veru

$1.44

-0.05 (-3.36%)

16:10
03/18/19
03/18
16:10
03/18/19
16:10
Initiation
Veru initiated  »

Veru initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 26

    Mar

CYAD

Celyad

$21.35

(0.00%)

16:10
03/18/19
03/18
16:10
03/18/19
16:10
Hot Stocks
Celyad provides update on CYAD-01 at R&D Day »

Celyad presented at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 19

    Mar

  • 20

    Mar

  • 04

    Apr

  • 09

    Apr

CRBP

Corbus Pharmaceuticals

$6.90

0.18 (2.68%)

16:10
03/18/19
03/18
16:10
03/18/19
16:10
Initiation
Corbus Pharmaceuticals initiated  »

Corbus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

TACO

Del Taco

$10.59

0.46 (4.54%)

16:09
03/18/19
03/18
16:09
03/18/19
16:09
Earnings
Del Taco sees FY19 adjusted EPS 47c-52c, consensus 58c »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

AKBA

Akebia

$8.19

0.01 (0.12%)

16:09
03/18/19
03/18
16:09
03/18/19
16:09
Earnings
Akebia reports Q4 revenue $59.9M, consensus $73.67M. »

Reports Q4 net loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

TACO

Del Taco

$10.58

0.45 (4.44%)

16:08
03/18/19
03/18
16:08
03/18/19
16:08
Earnings
Del Taco reports Q4 adjusted EPS 18c, consensus 19c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

TORC

ResTORbio

$8.96

0.26 (2.99%)

16:08
03/18/19
03/18
16:08
03/18/19
16:08
Hot Stocks
ResTORbio reports Q4 EPS (21c), consensus (34c) »

Cash, cash equivalents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUI

CUI Global

$1.41

0.065 (4.85%)

16:07
03/18/19
03/18
16:07
03/18/19
16:07
Hot Stocks
CUI Global agrees to terms for approximate 20% interset in Virtual Power Systems »

The company agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

ROP

Roper Technologies

$331.34

5.2 (1.59%)

16:07
03/18/19
03/18
16:07
03/18/19
16:07
Hot Stocks
Roper Technologies to acquire Foundry »

Roper Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEAM

Atlassian

$111.01

0.74 (0.67%)

16:06
03/18/19
03/18
16:06
03/18/19
16:06
Hot Stocks
Atlassian to acquire AgileCraft for $166M »

Atlassian Corp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRY

Tilray

$72.33

-0.2 (-0.28%)

16:06
03/18/19
03/18
16:06
03/18/19
16:06
Earnings
Tilray reports Q4 EPS (33c), consensus (12c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

CUI

CUI Global

$1.41

0.065 (4.85%)

16:06
03/18/19
03/18
16:06
03/18/19
16:06
Earnings
CUI Global reports Q4 EPS (27c), consensus (6c) »

Reports Q4 revenue $27M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

CYTK

Cytokinetics

$8.22

0.43 (5.52%)

, AMGN

Amgen

$191.69

0.58 (0.30%)

16:05
03/18/19
03/18
16:05
03/18/19
16:05
Hot Stocks
Cytokinetics COSMIC-HF study meets primary pharmacokinetic objective »

Cytokinetics (CYTK)…

CYTK

Cytokinetics

$8.22

0.43 (5.52%)

AMGN

Amgen

$191.69

0.58 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNI

Canadian National

$88.56

0.94 (1.07%)

16:05
03/18/19
03/18
16:05
03/18/19
16:05
Hot Stocks
CN investing more than $245M to strengthen Saskatchewan rail infrastructure »

CN it plans to invest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

GS

Goldman Sachs

$202.36

4.09 (2.06%)

16:04
03/18/19
03/18
16:04
03/18/19
16:04
Periodicals
Goldman intends to interview two diverse candidates for any open job, WSJ says »

Goldman Sachs managers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVTI

Covenant Transportation

$21.46

-0.37 (-1.69%)

16:04
03/18/19
03/18
16:04
03/18/19
16:04
Earnings
Covenant Transportation sees Q1 EPS 18c-26c, consensus 36c »

Covenant CEO David Parker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAM

Boston Beer

$311.83

5.025 (1.64%)

, UBER

Uber

$0.00

(0.00%)

16:03
03/18/19
03/18
16:03
03/18/19
16:03
Hot Stocks
Boston Beer names Meghan Joyce to Board of Directors »

The Boston Beer Company…

SAM

Boston Beer

$311.83

5.025 (1.64%)

UBER

Uber

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.